Beckley Psytech Begins Phase IIa Study Of Psychedelic Compound To Treat Depression
Clinical-stage private biotech company Beckley Psytech Ltd announced that the first patient has been dosed in their Phase IIa study of BPL-003, a synthetic formulation of the psychedelic compound
